Victor Jimenez Zepeda, MD, PhD, University of Calgary, Calgary, Canada, discusses the challenges in treating relapsed/refractory (R/R) amyloidosis. Identifying when a patient needs treatment and what treatment to use are the first challenges faced by clinicians. Other challenges remain regarding how to treat patients that progress after daratumumab, and how to approach those with the t(11;14) translocation. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.